Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction

Area of Science:

• Cardiology
• Immunology
• Clinical Risk Stratification

Background:

• Previous research indicated platelet FcγRIIa (pFCG) can stratify myocardial infarction (MI) patient risk.
• A single-center study suggested pFCG levels differentiate risk for subsequent MI, stroke, and death.

Purpose of the Study:

• To validate the prognostic significance of pFCG in a larger, multi-center cohort.
• To assess the association between pFCG levels and cardiovascular event risk in MI patients.

Main Methods:

• Prospective, noninterventional trial involving 800 patients with type 1 MI across 25 centers.
• Patients met criteria including age ≥65, multivessel coronary artery disease, prior MI, chronic kidney disease, or diabetes.
• Flow cytometry quantified pFCG; patients were followed for 6 months for major adverse cardiovascular events.

Main Results:

• High pFCG levels were associated with a significantly increased risk of the primary composite endpoint (MI, stroke, death) (HR: 2.09).
• Both death (HR: 2.57) and recurrent MI (HR: 3.24) were more frequent in patients with high pFCG.
• Antithrombotic therapy use was similar between high and low pFCG groups, suggesting pFCG is an independent risk marker.

Conclusions:

• Quantification of pFCG effectively identifies MI patients at elevated risk for subsequent cardiovascular events.
• This prognostic information can guide clinical decisions on antiplatelet therapy intensity and duration.
• The study provides robust, multi-center validation for pFCG as a cardiovascular risk biomarker.